Cargando…

Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies

Inflammation and B-cell hyperactivation have been associated with non-Hodgkin lymphoma development. This prospective analysis aimed to further elucidate pre-diagnosis plasma immune marker profiles associated with non-Hodgkin lymphoma risk. We identified 598 incident lymphoma cases and 601 matched co...

Descripción completa

Detalles Bibliográficos
Autores principales: Epstein, Mara M., Rosner, Bernard, Breen, Elizabeth C., Batista, Julie L., Giovannucci, Edward L., Magpantay, Larry, Aster, Jon C., Rodig, Scott J., Bertrand, Kimberly A., Laden, Francine, Martínez-Maza, Otoniel, Birmann, Brenda M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165815/
https://www.ncbi.nlm.nih.gov/pubmed/29930163
http://dx.doi.org/10.3324/haematol.2017.183236
_version_ 1783359910496436224
author Epstein, Mara M.
Rosner, Bernard
Breen, Elizabeth C.
Batista, Julie L.
Giovannucci, Edward L.
Magpantay, Larry
Aster, Jon C.
Rodig, Scott J.
Bertrand, Kimberly A.
Laden, Francine
Martínez-Maza, Otoniel
Birmann, Brenda M.
author_facet Epstein, Mara M.
Rosner, Bernard
Breen, Elizabeth C.
Batista, Julie L.
Giovannucci, Edward L.
Magpantay, Larry
Aster, Jon C.
Rodig, Scott J.
Bertrand, Kimberly A.
Laden, Francine
Martínez-Maza, Otoniel
Birmann, Brenda M.
author_sort Epstein, Mara M.
collection PubMed
description Inflammation and B-cell hyperactivation have been associated with non-Hodgkin lymphoma development. This prospective analysis aimed to further elucidate pre-diagnosis plasma immune marker profiles associated with non-Hodgkin lymphoma risk. We identified 598 incident lymphoma cases and 601 matched controls in Nurses’ Health Study and Health Professionals Follow-up Study participants with archived pre-diagnosis plasma samples and measured 13 immune marker levels with multiplexed immunoassays. Using multivariable logistic regression we calculated Odds Ratios (OR) and 95% Confidence Intervals (CI) per standard deviation unit increase in biomarker concentration for risk of non-Hodgkin lymphoma and major histological subtype, stratifying additional models by years (<5, 5 to <10, ≥10) after blood draw. Soluble interleukin-2 receptor-α, CXC chemokine ligand 13, soluble CD30, and soluble tumor necrosis factor receptor-2 were individually positively associated, and B-cell activating factor of the tumor necrosis factor family inversely associated, with all non-Hodgkin lymphoma and one or more subtypes. The biomarker combinations associated independently with lymphoma varied somewhat by subtype and years after blood draw. Of note, the unexpected inverse association between B-cell activating factor and chronic lymphocytic leukemia/small lymphocytic lymphoma risk (OR: 95%CI: 0.51, 0.43-0.62) persisted more than ten years after blood draw (OR: 0.70; 95%CI: 0.52-0.93). In conclusion, immune activation precedes non-Hodgkin lymphoma diagnosis by several years. Decreased B-cell activating factor levels may denote nascent chronic lymphocytic leukemia many years pre-diagnosis.
format Online
Article
Text
id pubmed-6165815
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Ferrata Storti Foundation
record_format MEDLINE/PubMed
spelling pubmed-61658152018-10-04 Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies Epstein, Mara M. Rosner, Bernard Breen, Elizabeth C. Batista, Julie L. Giovannucci, Edward L. Magpantay, Larry Aster, Jon C. Rodig, Scott J. Bertrand, Kimberly A. Laden, Francine Martínez-Maza, Otoniel Birmann, Brenda M. Haematologica Article Inflammation and B-cell hyperactivation have been associated with non-Hodgkin lymphoma development. This prospective analysis aimed to further elucidate pre-diagnosis plasma immune marker profiles associated with non-Hodgkin lymphoma risk. We identified 598 incident lymphoma cases and 601 matched controls in Nurses’ Health Study and Health Professionals Follow-up Study participants with archived pre-diagnosis plasma samples and measured 13 immune marker levels with multiplexed immunoassays. Using multivariable logistic regression we calculated Odds Ratios (OR) and 95% Confidence Intervals (CI) per standard deviation unit increase in biomarker concentration for risk of non-Hodgkin lymphoma and major histological subtype, stratifying additional models by years (<5, 5 to <10, ≥10) after blood draw. Soluble interleukin-2 receptor-α, CXC chemokine ligand 13, soluble CD30, and soluble tumor necrosis factor receptor-2 were individually positively associated, and B-cell activating factor of the tumor necrosis factor family inversely associated, with all non-Hodgkin lymphoma and one or more subtypes. The biomarker combinations associated independently with lymphoma varied somewhat by subtype and years after blood draw. Of note, the unexpected inverse association between B-cell activating factor and chronic lymphocytic leukemia/small lymphocytic lymphoma risk (OR: 95%CI: 0.51, 0.43-0.62) persisted more than ten years after blood draw (OR: 0.70; 95%CI: 0.52-0.93). In conclusion, immune activation precedes non-Hodgkin lymphoma diagnosis by several years. Decreased B-cell activating factor levels may denote nascent chronic lymphocytic leukemia many years pre-diagnosis. Ferrata Storti Foundation 2018-10 /pmc/articles/PMC6165815/ /pubmed/29930163 http://dx.doi.org/10.3324/haematol.2017.183236 Text en Copyright © 2018 Ferrata Storti Foundation Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.
spellingShingle Article
Epstein, Mara M.
Rosner, Bernard
Breen, Elizabeth C.
Batista, Julie L.
Giovannucci, Edward L.
Magpantay, Larry
Aster, Jon C.
Rodig, Scott J.
Bertrand, Kimberly A.
Laden, Francine
Martínez-Maza, Otoniel
Birmann, Brenda M.
Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies
title Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies
title_full Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies
title_fullStr Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies
title_full_unstemmed Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies
title_short Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies
title_sort pre-diagnosis plasma immune markers and risk of non-hodgkin lymphoma in two prospective cohort studies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165815/
https://www.ncbi.nlm.nih.gov/pubmed/29930163
http://dx.doi.org/10.3324/haematol.2017.183236
work_keys_str_mv AT epsteinmaram prediagnosisplasmaimmunemarkersandriskofnonhodgkinlymphomaintwoprospectivecohortstudies
AT rosnerbernard prediagnosisplasmaimmunemarkersandriskofnonhodgkinlymphomaintwoprospectivecohortstudies
AT breenelizabethc prediagnosisplasmaimmunemarkersandriskofnonhodgkinlymphomaintwoprospectivecohortstudies
AT batistajuliel prediagnosisplasmaimmunemarkersandriskofnonhodgkinlymphomaintwoprospectivecohortstudies
AT giovannucciedwardl prediagnosisplasmaimmunemarkersandriskofnonhodgkinlymphomaintwoprospectivecohortstudies
AT magpantaylarry prediagnosisplasmaimmunemarkersandriskofnonhodgkinlymphomaintwoprospectivecohortstudies
AT asterjonc prediagnosisplasmaimmunemarkersandriskofnonhodgkinlymphomaintwoprospectivecohortstudies
AT rodigscottj prediagnosisplasmaimmunemarkersandriskofnonhodgkinlymphomaintwoprospectivecohortstudies
AT bertrandkimberlya prediagnosisplasmaimmunemarkersandriskofnonhodgkinlymphomaintwoprospectivecohortstudies
AT ladenfrancine prediagnosisplasmaimmunemarkersandriskofnonhodgkinlymphomaintwoprospectivecohortstudies
AT martinezmazaotoniel prediagnosisplasmaimmunemarkersandriskofnonhodgkinlymphomaintwoprospectivecohortstudies
AT birmannbrendam prediagnosisplasmaimmunemarkersandriskofnonhodgkinlymphomaintwoprospectivecohortstudies